{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04196491\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"KarMMa-4","nct_id":"NCT04196491","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=karmma-4-nct04196491. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"KarMMa-4","arms":[{"description":"* bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 800 x 10\\^6 CAR+ T cells after receiving lymphodepleting chemotherapy with a planned starting dose of 450 x 10\\^6 CAR+ T cells.\n* Lenalidomide maintenance therapy is recommended for all patients and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later","label":"Dose Escalation","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-06-07","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":13,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"bb2121","type":"BIOLOGICAL"},{"name":"Fludarabine","type":"DRUG"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"}],"last_update":"2023-08-23","lead_sponsor":"Celgene","official_title":"A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-06-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Dose-limiting toxicity (DLT) rates","timeFrame":"Up to completion of DLT period after last subject bb2121 infused"},{"measure":"Adverse Events (AEs)","timeFrame":"Approximately 2 years after last subject bb2121 infused"}],"references":[{"citation":"Parmar H, Vesole DH, Biran N. From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma? Cancer J. 2021 May-Jun 01;27(3):190-195. doi: 10.1097/PPO.0000000000000522.","pmid":"34549906","type":"DERIVED"}],"start_date":{"date":"2020-05-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)","url":"https://clinicaltrials.gov/study/NCT04196491"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/karmma-4-nct04196491"}